Vimta Labs (BSE:524394) - Share price, News & Analysis

524394 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	4/6

524394 Stock Overview

Vimta Labs Limited provides contract research and testing services in India and internationally.

Rewards

Trading at 43.4% below our estimate of its fair value

Earnings grew by 93.1% over the past year

Risk Analysis

Unstable dividend track record

Does not have a meaningful market cap (₹8B)

Vimta Labs Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vimta Labs
Historical stock prices
Current Share Price	₹344.80
52 Week High	₹453.00
52 Week Low	₹216.00
Beta	1.06
1 Month Change	-9.00%
3 Month Change	2.90%
1 Year Change	58.42%
3 Year Change	76.14%
5 Year Change	189.87%
Change since IPO	31,245.46%

Shareholder Returns

	524394	IN Life Sciences	IN Market
7D	-0.9%	1.5%	3.4%
1Y	58.4%	3.1%	9.5%

Return vs Industry: 524394 exceeded the Indian Life Sciences industry which returned 3.1% over the past year.

Return vs Market: 524394 exceeded the Indian Market which returned 9.5% over the past year.

Price Volatility

Is 524394's price volatile compared to industry and market?
524394 volatility
524394 Average Weekly Movement	7.0%
Life Sciences Industry Average Movement	7.1%
Market Average Movement	7.2%
10% most volatile stocks in IN Market	10.0%
10% least volatile stocks in IN Market	4.8%

Stable Share Price: 524394 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 524394's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1984	1,096	Harita Vasireddi	https://www.vimta.com

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers laboratory, food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. It serves pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and various other industries.

Vimta Labs Fundamentals Summary

How do Vimta Labs's earnings and revenue compare to its market cap?
524394 fundamental statistics
Market Cap	₹7.62b
Earnings (TTM)	₹413.30m
Revenue (TTM)	₹2.78b

18.4x

P/E Ratio

2.7x

P/S Ratio

Is 524394 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
524394 income statement (TTM)
Revenue	₹2.78b
Cost of Revenue	₹791.96m
Gross Profit	₹1.99b
Other Expenses	₹1.58b
Earnings	₹413.30m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	18.69
Gross Margin	71.54%
Net Profit Margin	14.85%
Debt/Equity Ratio	8.3%

How did 524394 perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

11%

Payout Ratio

Valuation

Is Vimta Labs undervalued compared to its fair value and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

43.4%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 524394 (₹344.8) is trading below our estimate of fair value (₹608.78)

Significantly Below Fair Value: 524394 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 524394 is good value based on its PE Ratio (18.4x) compared to the Indian Life Sciences industry average (34.9x).

PE vs Market: 524394 is good value based on its PE Ratio (18.4x) compared to the Indian market (20.5x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524394's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 524394 is overvalued based on its PB Ratio (3.3x) compared to the IN Life Sciences industry average (2.9x).

Future Growth

How is Vimta Labs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

21.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vimta Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Vimta Labs performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

19.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524394 has high quality earnings.

Growing Profit Margin: 524394's current net profit margins (14.9%) are higher than last year (10.1%).

Past Earnings Growth Analysis

Earnings Trend: 524394's earnings have grown by 19.3% per year over the past 5 years.

Accelerating Growth: 524394's earnings growth over the past year (93.1%) exceeds its 5-year average (19.3% per year).

Earnings vs Industry: 524394 earnings growth over the past year (93.1%) exceeded the Life Sciences industry 37.3%.

Return on Equity

High ROE: 524394's Return on Equity (17.7%) is considered low.

Financial Health

How is Vimta Labs's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 524394's short term assets (₹1.2B) exceed its short term liabilities (₹477.5M).

Long Term Liabilities: 524394's short term assets (₹1.2B) exceed its long term liabilities (₹254.7M).

Debt to Equity History and Analysis

Debt Level: 524394's net debt to equity ratio (3.4%) is considered satisfactory.

Reducing Debt: 524394's debt to equity ratio has reduced from 32% to 8.3% over the past 5 years.

Debt Coverage: 524394's debt is well covered by operating cash flow (305.4%).

Interest Coverage: 524394's interest payments on its debt are well covered by EBIT (38x coverage).

Balance Sheet

Dividend

What is Vimta Labs's current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.58%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 524394's dividend (0.58%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).

High Dividend: 524394's dividend (0.58%) is low compared to the top 25% of dividend payers in the Indian market (1.6%).

Stability and Growth of Payments

Stable Dividend: 524394's dividend payments have been volatile in the past 10 years.

Growing Dividend: 524394's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (10.7%), 524394's dividend payments are thoroughly covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (21.7%), 524394's dividend payments are well covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure

CEO

Harita Vasireddi (47 yo)

8.83yrs

Tenure

₹6,720,000

Compensation

Ms. Harita Vasireddi, B. Pharm, MBA (USA) has been the Managing Director of Vimta Labs Ltd. since July 15, 2013 and serves as its Whole Time Director. She was a Member of Scientific Advisory Board at Vimta...

CEO Compensation Analysis

Compensation vs Market: Harita's total compensation ($USD86.36K) is above average for companies of similar size in the Indian market ($USD38.56K).

Compensation vs Earnings: Harita's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: 524394's management team is seasoned and experienced (5 years average tenure).

Board Members

Experienced Board: 524394's board of directors are considered experienced (3.7 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2022/03/31
Annual Earnings	2022/03/31